- Home
- AGX vs STOK Comparison
AGX vs STOK Comparison
Compare AGX & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGX
- STOK
- Stock Information
- Founded
- AGX 1961
- STOK 2014
- Country
- AGX United States
- STOK United States
- Employees
- AGX N/A
- STOK N/A
- Industry
- AGX Engineering & Construction
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- AGX Consumer Discretionary
- STOK Health Care
- Exchange
- AGX Nasdaq
- STOK Nasdaq
- Market Cap
- AGX 1.2B
- STOK 838.2M
- IPO Year
- AGX N/A
- STOK 2019
- Fundamental
- Price
- AGX $90.08
- STOK $13.91
- Analyst Decision
- AGX Strong Buy
- STOK Strong Buy
- Analyst Count
- AGX 2
- STOK 7
- Target Price
- AGX $77.50
- STOK $21.40
- AVG Volume (30 Days)
- AGX 241.7K
- STOK 406.3K
- Earning Date
- AGX 09-05-2024
- STOK 11-05-2024
- Dividend Yield
- AGX 1.32%
- STOK N/A
- EPS Growth
- AGX 20.22
- STOK N/A
- EPS
- AGX 3.19
- STOK N/A
- Revenue
- AGX $713,006,000.00
- STOK $15,157,000.00
- Revenue This Year
- AGX $32.88
- STOK $78.03
- Revenue Next Year
- AGX $13.20
- STOK $12.23
- P/E Ratio
- AGX $28.52
- STOK N/A
- Revenue Growth
- AGX 48.03
- STOK 71.38
- 52 Week Low
- AGX $39.74
- STOK $3.35
- 52 Week High
- AGX $95.73
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- AGX 64.93
- STOK 45.86
- Support Level
- AGX $86.98
- STOK $13.62
- Resistance Level
- AGX $95.73
- STOK $15.92
- Average True Range (ATR)
- AGX 3.44
- STOK 0.88
- MACD
- AGX 1.64
- STOK -0.06
- Stochastic Oscillator
- AGX 72.92
- STOK 19.31
About AGX Argan Inc.
Argan Inc is a United States-base construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derive majority revenue.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.